The value of assessment tests in patients with acute exacerbation of chronic obstructive pulmonary disease

American Journal of the Medical Sciences

Volumn 347, Issue 5, 2014, Pages 393-399

  Zhao, Yun Feng ^a   Jiang, Yan Ping ^b   Zhou, Lin Fu ^c   Wu, Xue Ling ^d  

^a Pudong New Area Gongli Hospital   (China)

^b Hospital of Chinese PLA   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

C reactive protein.; Chronic obstructive pulmonary disease; COPD assessment test; Copeptin; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; COPEPTIN; PROCALCITONIN;

ACUTE DISEASE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASSESSMENT TEST; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; RECURRENT DISEASE; SCORING SYSTEM;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RECURRENCE; RESPIRATORY FUNCTION TESTS;

EID: 84899476390     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31829a63b1     Document Type: Article

References (37)

1. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
2. Steinmetz J, Rasmussen LS, Nielsen SL. Long-term prognosis for patients with COPD treated in the prehospital setting: is it influenced by hospital admission? Chest 2006;130:676-80.
3. Pedone C, Scarlata S, Sorino C, et al. Does mild COPD affect prognosis in the elderly? BMC Pulm Med 2010;10:35.
4. Azarisman MS, Fauzi MA, Faizal MP, et al. The SAFE (SGRQ score, air-flow limitation and exercise tolerance) index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad Med J 2007;83:492-7.
5. Burgos F. Quality of forced spirometry in primary care, impact on the COPD treatment. Arch Bronconeumol 2011;47:224-5.
6. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-67.
7. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD assessment test. Eur Respir J 2009;34:648-54.
8. Chai JJ, Liu T, Cai BQ. Evaluation of clinical significance of chronic obstructive pulmonary disease assessment test [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2011;34:256-8.
9. MorgenthalerNG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9.
10. Zulfikaroglu E, Islimye M, Tonguc EA, et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res 2011;37:1198-202.
11. Urwyler SA, Schuetz P, Fluri F, et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010;41: 1564-7.
12. Muller B,Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-52.
13. Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009;30:1187-94.
14. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010;16(suppl 1):S37-44.
15. Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: a review. Pathology 2007;39:383-90.
16. Petrikkos GL, Christofilopoulou SA, Tentolouris NK, et al. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis 2005;24:272-5.
17. Pauwels RA, Buist AS, Ma P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001;46:798-825.
18. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
19. Nagata K, Tomii K, Otsuka K, et al. Evaluation of the COPD assessment test (CAT) for measurement of health-related quality of life in patients with interstitial lung disease. Respirology 2012;17:506-12.
20. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96.
21. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations-comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010;8:39.
22. Vestbo J, Prescott E, Lange P, et al. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir Med 1998;92:772-6.
23. Takigawa N, Tada A, Soda R, et al. Distance and oxygen desaturation in 6-min walk test predict prognosis in COPD patients. Respir Med 2007;101:561-7.
24. Halpin DM, Decramer M, Celli B, et al. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012;7:653-61.
25. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005;26:414-9.
26. Andenaes R, Moum T, Kalfoss MH, et al. Changes in health status, psychological distress, and quality of life in COPD patients after hospitalization. Qual Life Res 2006;15:249-57.
27. Messer B, Griffiths J, Baudouin SV. The prognostic variables predictive of mortality in patients with an exacerbation of COPD admitted to the ICU: an integrative review. QJM 2012;105: 115-26.
28. Oga T, Tsukino M, Hajiro T, et al. Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011;6:521-6.
29. Zhou LF, Chen L, Zhu Q, et al. Unusual life-threatening Rosai-Dorfman disease of the trachea: role of NF-kB. Thorax 2010;65: 927-9.
30. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26:2500-4.
31. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006;91:4381-6.
32. Hütter BO, Würtemberger G. Functional capacity (dyspnea) and quality of life in patients with chronic obstructive lung disease (COPD): instruments of assessment and methodological aspects [in German]. Pneumologie 1999;53:133-42.
33. Renom F, Yanez A, Garau M, et al. Prognosis of COPD patients requiring frequent hospitalization: role of airway infection. Respir Med 2010;104:840-8.
34. Akagi K, Berdusco ET, Challis JR. Cortisol inhibits ACTH but not the AVP response to hypoxaemia in fetal lambs at days 123-128 of gestation. J Dev Physiol 1990;14:319-24.
35. Westphal M, Sielenkamper AW, Van Aken H, et al. Dopexamine reverses the vasopressin associated impairment in tissue oxygen supply but decreases systemic blood pressure in ovine endotoxemia. Anesth Analg 2004;99:878-85, table of contents.
36. Katan M, Morgenthaler NG, Dixit KC, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 2007;92:2640-3.
37. Hoorn EJ, van Wolfswinkel ME, Hesselink DA, et al. Hyponatraemia in imported malaria: the pathophysiological role of vasopressin. Malar J 2012;11:26.